489
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Glaucoma: challenges and opportunities

ORCID Icon, ORCID Icon & ORCID Icon

References

  • Access Economics. Clear focus. The economic impact of vision loss in Australia in 2009. [accessed 2023 Dec 16]. https://www.vision2020australia.org.au/wp-content/uploads/2019/06/Access_Economics_Clear_Focus_Full_Report.pdf.
  • Nyman SR, Gosney MA, Victor CR. Psychosocial impact of visual impairment in working-age adults. Br J Ophthalmol 2010; 94: 1427–1431. doi:10.1136/bjo.2009.164814.
  • Tham YC, Li X, Wong TY et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014; 121: 2081–2090. doi:10.1016/j.ophtha.2014.05.013.
  • Mitchell P, Smith W, Attebo K et al. Prevalence of open-angle glaucoma in Australia. The blue mountains eye study. Ophthalmology 1996; 103: 1661–1669. doi:10.1016/S0161-6420(96)30449-1.
  • Keel S, Xie J, Foreman J et al. Prevalence of glaucoma in the Australian national eye health survey. Br J Ophthalmol 2019; 103: 191–195. doi:10.1136/bjophthalmol-2017-311786.
  • Phu J, Agar A, Wang H et al. Management of open-angle glaucoma by primary eye-care practitioners: toward a personalised medicine approach. Clin Exp Optom 2021; 104: 367–84. doi:10.1111/cxo.13114.
  • Phu J, Rafla D, Kalloniatis M. Which glaucoma patients benefit from 10-2 visual field testing? Proposing the functional vulnerability zone framework. Clin Exp Optom 2024; 1–13. (in press). doi:10.1080/08164622.2023.2288183.
  • Green S, Ng RJ, Phillips G et al. Glaucoma Agreement in New Zealand (GAINZ). Clin Exp Optom 2024; 1–9. (in press). doi:10.1080/08164622.2023.2291063.
  • Hasan Md M, Phu J, Sowmya A et al. Artificial intelligence in the diagnosis of glaucoma and neurodegenerative diseases. Clin Exp Optom 2024; 1–17. (in press). doi:10.1080/08164622.2023.2235346.
  • van Koeverden ΑΚ, Afiat BA, Nguyen CTO et al. Understanding how ageing impacts ganglion cell susceptibility to injury in glaucoma. Clin Exp Optom 2024; 1–9. (in press). doi:10.1080/08164622.2023.2279734.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.